{"id":"https://openalex.org/W67197765","doi":null,"title":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.","display_name":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.","publication_year":2000,"publication_date":"2000-03-01","ids":{"openalex":"https://openalex.org/W67197765","mag":"67197765","pmid":"https://pubmed.ncbi.nlm.nih.gov/10840932"},"language":"en","primary_location":{"id":"pmid:10840932","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10840932","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of experimental & clinical cancer research : CR","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081136844","display_name":"L. Serrone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152244","display_name":"Instituto Nazionale Tumori Regina Elena","ror":"https://ror.org/04mgfev69","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4387152244"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"L Serrone","raw_affiliation_strings":["I Division of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"I Division of Medical Oncology, Regina Elena Institute for Cancer Research, Rome, Italy","institution_ids":["https://openalex.org/I4387152244"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022654643","display_name":"Massimo Zeuli","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Zeuli","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049975699","display_name":"Fabio Massimo Sega","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F M Sega","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5101951892","display_name":"Francesco Cognetti","orcid":"https://orcid.org/0000-0001-8498-151X","observed_orcids":["https://orcid.org/0000-0001-8498-151X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F Cognetti","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.2528,"has_fulltext":false,"cited_by_count":348,"citation_normalized_percentile":{"value":0.87573338,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"19","issue":"1","first_page":"21","last_page":"34"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dacarbazine","display_name":"dacarbazine","score":0.9129999876022339},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.871999979019165},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.7400000095367432},{"id":"https://openalex.org/keywords/nitrosourea","display_name":"nitrosourea","score":0.7559999823570251},{"id":"https://openalex.org/keywords/tamoxifen","display_name":"tamoxifen","score":0.9480000138282776},{"id":"https://openalex.org/keywords/bleomycin","display_name":"bleomycin","score":0.7360000014305115},{"id":"https://openalex.org/keywords/vinblastine","display_name":"vinblastine","score":0.7630000114440918},{"id":"https://openalex.org/keywords/carmustine","display_name":"BCNU","score":0.8320000171661377},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.9440000057220459},{"id":"https://openalex.org/keywords/chemoresistance","display_name":"chemoresistance","score":0.8709999918937683},{"id":"https://openalex.org/keywords/long-term-survival","display_name":"long-term survival","score":0.7059999704360962},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6959999799728394}],"concepts":[{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.9142501354217529},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8437269330024719},{"id":"https://openalex.org/C2780147359","wikidata":"https://www.wikidata.org/wiki/Q415869","display_name":"Carmustine","level":4,"score":0.7230492234230042},{"id":"https://openalex.org/C2779434656","wikidata":"https://www.wikidata.org/wiki/Q415378","display_name":"Lomustine","level":5,"score":0.7162399291992188},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.658918559551239},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5702381134033203},{"id":"https://openalex.org/C2777132456","wikidata":"https://www.wikidata.org/wiki/Q282629","display_name":"Vinblastine","level":3,"score":0.5533789396286011},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5448437333106995},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.5374013185501099},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.52911776304245},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.5025129318237305},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.48421382904052734},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4523308575153351},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4107387363910675},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.1728469431400299},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.14529573917388916}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001761","descriptor_name":"Bleomycin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002330","descriptor_name":"Carmustine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013629","descriptor_name":"Tamoxifen","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:10840932","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10840932","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of experimental & clinical cancer research : CR","raw_type":"Journal Article"},{"id":"mag:67197765","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10840932","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4212896004","https://openalex.org/W4255098699","https://openalex.org/W3192823395","https://openalex.org/W7098143856","https://openalex.org/W2002288639","https://openalex.org/W2009640903","https://openalex.org/W2032598681","https://openalex.org/W2396108008","https://openalex.org/W1983984116","https://openalex.org/W7100232811"],"abstract_inverted_index":{"Dacarbazine":[0],"(DTIC)":[1],"is":[2,206,298],"the":[3,8,130,163,244,267,273,285,310,313,317,324,332,335],"only":[4],"single-agent":[5],"approved":[6],"by":[7],"Food":[9],"and":[10,40,52,87,115,117,121,133,178,323],"Drug":[11],"Administration":[12],"for":[13,320],"treating":[14],"metastatic":[15,127,262],"melanoma.":[16],"With":[17],"DTIC":[18,49,80,138,177,235,255],"as":[19,84,218],"single":[20,50],"agent,":[21],"an":[22],"approximately":[23],"20%":[24],"objective":[25],"response":[26,33,42,96,186],"rate":[27],"can":[28],"be":[29,301],"achieved":[30],"with":[31,162,191,211,284,289],"median":[32],"duration":[34],"of":[35,44,48,81,158,165,203,226,232,316,326],"5":[36],"to":[37,79,93,99,129,137,144,167,189,197,300],"6":[38],"months":[39],"complete":[41,194],"rates":[43],"5%.":[45],"Current":[46],"status":[47],"agent":[51],"DTIC-based":[53,252],"combination":[54,68,108,173],"chemotherapy":[55,253],"has":[56,90,183,257,269],"been":[57,75,91,259,282],"extensively":[58],"reviewed":[59],"in":[60,101,200,241,261,303,334],"this":[61],"article.":[62],"Moreover,":[63],"future":[64],"directions":[65],"including":[66],"new":[67,71,327],"chemotherapies":[69],"and/or":[70,288],"therapeutical":[72,328],"approaches":[73],"have":[74,123,142,153,281],"considered.":[76],"The":[77,171],"addition":[78,164],"agents":[82],"such":[83],"cisplatin,":[85],"nitrosoureas":[86],"tubular":[88],"toxins":[89],"reported":[92,283],"yield":[94],"high":[95,185,290],"rates,":[97,187],"up":[98,188,196],"40%,":[100],"single-institution":[102],"phase":[103,229,306],"II":[104],"trials.":[105,308],"Historically,":[106],"promising":[107],"regimens":[109,295],"like":[110],"BOLD":[111],"(bleomycin,":[112],"vincristine,":[113],"lomustine":[114],"DTIC)":[116,122],"CVD":[118],"(cisplatin,":[119,175],"vinblastine":[120],"induced":[124],"responses":[125],"on":[126,147],"lesions":[128],"liver,":[131],"bone":[132],"brain,":[134],"commonly":[135],"unresponsive":[136],"alone,":[139,236],"even":[140,221],"though":[141,222],"failed":[143],"produce":[145],"impact":[146],"patient":[148],"survival.":[149],"Several":[150],"other":[151,212,311],"studies":[152],"suggested":[154],"a":[155,201,227,248],"significant":[156],"enhancement":[157],"antitumor":[159],"effect":[160],"associated":[161],"tamoxifen":[166],"various":[168],"cytotoxic":[169],"regimens.":[170],"four-drug":[172],"CBDT":[174,217,233],"carmustine,":[176],"tamoxifen)":[179],"or":[180,254],"\"Dartmouth":[181,286],"regimen\"":[182,287],"yielded":[184],"55%,":[190],"continuous,":[192],"maintained,":[193],"responses,":[195],"82":[198],"months,":[199],"subset":[202],"patients,":[204],"that":[205],"considerably":[207],"longer":[208],"than":[209],"observed":[210],"combinations.":[213],"Some":[214],"authors":[215],"recommend":[216],"reference":[219],"therapy,":[220],"recently":[223],"presented":[224],"results":[225],"randomized":[228,305],"III":[230,307],"trial":[231],"versus":[234],"show":[237],"no":[238],"statistical":[239],"difference":[240],"survival":[242,249,268],"between":[243],"two":[245],"groups.":[246],"While":[247],"benefit":[250],"from":[251],"alone":[256],"never":[258],"shown":[260],"melanoma":[263,321],"patients":[264],"and,":[265],"therefore,":[266],"remained":[270],"unchanged":[271],"over":[272],"past":[274],"30":[275],"years,":[276],"some":[277],"long":[278],"term":[279],"survivors":[280],"dose":[291],"interleukin-2":[292],"(IL-2)":[293],"based":[294],"whose":[296],"role":[297],"going":[299],"defined":[302],"prospective":[304],"On":[309],"hand,":[312],"better":[314],"understanding":[315],"mechanisms":[318],"responsible":[319],"chemoresistance":[322],"development":[325],"strategies":[329],"could":[330],"change":[331],"scenario":[333],"next":[336],"future.":[337]},"counts_by_year":[{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":14},{"year":2022,"cited_by_count":16},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":18},{"year":2019,"cited_by_count":16},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":19},{"year":2016,"cited_by_count":18},{"year":2015,"cited_by_count":19},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":23},{"year":2012,"cited_by_count":18}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}